Canada markets close in 5 hours 5 minutes

Unity Biotechnology, Inc. (9U9.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.7706-0.0002 (-0.03%)
As of 03:44PM CEST. Market open.
Full screen
Previous Close0.7708
Open0.7560
Bid0.7708 x 0
Ask0.8014 x 0
Day's Range0.7560 - 0.7706
52 Week Range0.6435 - 4.1040
Volume777
Avg. Volume412
Market Cap53.737M
Beta (5Y Monthly)0.38
PE Ratio (TTM)N/A
EPS (TTM)-1.0240
Earnings DateAug 08, 2022 - Aug 12, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.86
  • GlobeNewswire

    UNITY Biotechnology, Inc. Reports First Quarter 2022 Financial Results and Business Updates

    -Completed enrollment in BEHOLD, the Phase 2 clinical trial of UBX1325 in DME; BEHOLD remains on track with 12-week safety and efficacy data anticipated by mid-year 2022- -Dosed first patient in ENVISION, the Phase 2 clinical trial of UBX1325 in wet age-related macular degeneration; ENVISION remains on track with 16-week results expected in Q4 2022- -As of March 31, 2022, UNITY had approximately $79.2 million in cash, cash equivalents and marketable securities, extending runway through Q1 2023-

  • GlobeNewswire

    UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular Diseases

    Cellular senescence biology in eye disease was a focal point at ARVO opening symposiumSOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, announced presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting featuring UBX1325 as a potential treatment for diabetic macular edema (DME) and wet age-related m

  • GlobeNewswire

    UNITY Biotechnology to Present Clinical Data at the Association for Research in Vision & Ophthalmology (ARVO) 2022 Annual Meeting

    SOUTH SAN FRANCISCO, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that clinical data results from the Phase 1 study of its lead senolytic candidate, UBX1325, in patients with diabetic macular edema and wet age-related macular degeneration will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meetin